Navigation Links
AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
Date:5/22/2008

WILMINGTON, Del., May 22 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it supports the revised Physician Payment Sunshine Act as part of the company's latest step to provide the public with more information about the way it does business.

Sponsored by Sens. Charles Grassley of Iowa and Herb Kohl of Wisconsin, the legislation would create a national registry of payments that biopharmaceutical companies, device manufacturers and medical supply companies make to medical organizations and health care providers.

"AstraZeneca believes that providing information to the public about our company, our products and how we do business is integral to improving patient health," said Tony Zook, President and CEO, AstraZeneca Pharmaceuticals, LP, U.S. "We are pleased to support this legislation that will create greater transparency around our relationships with physicians, while helping the public understand how we work with health care providers."

Zook praised Sens. Grassley and Kohl for their leadership on the legislation -- and especially for creating a single uniform registry that would capture payments made to physicians by biopharmaceutical companies, device manufacturers and medical supply companies. "This is the best approach to provide physician payment information to patients," Zook said.

AstraZeneca is proud that it improves patient health by helping ensure physicians are knowledgeable about our products and patient assistance programs, and by providing physicians with timely, relevant information that enables them to make the best treatment decisions for their patients.

In supporting the Physician Payment Sunshine Act, AstraZeneca builds on the transparency initiative it launched in March. AstraZeneca previously announced it will publicly share additional or enhanced information about its policy positions, political contributions, medical education grants, contributions to nonprofit organizations, and post-marketing study commitments, as well as making information on its compliance program and clinical trials more visible on its Web site.

Beginning at various stages this year, elements of the company's previously announced transparency initiative will be available at AstraZeneca's U.S. Web site http://www.astrazeneca-us.com, in an effort to better inform the public about how the company conducts its business and how it is helping patients through research and support for external organizations.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
10. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
11. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):